1. A pharmaceutical composition formulated for topical application to an epithelial tissue barrier surface comprising a soluble, antigen binding polypeptide and a pharmaceutically acceptable carrier, diluent or excipient, wherein said polypeptide is capable of passing through at least one or more epithelial in less than 8 h in the absence of a penetration enhancer, and in which said fintigen binding polypeptide is a single chain antibody containing the sequence of SEQ.ID: 12, SEQ.ID: 13, SEQ.ID: 18, SEQ.ID: 19, SEQ.ID: 20 or SEQ.ID: 21.2. The pharmaceutical composition according to claim 1, wherein said tissue barrier is the surface of the eye, nasal cavity, oral cavity, intestinal tract, skin, mucous membrane of the mouth and genitourinary tract, joints and joints of the joints, brain and spine. The pharmaceutical composition according to claim 1, which is intended for topical application to the eye. The pharmaceutical composition according to claim 3, formulated to achieve an intraocular concentration of an antigen binding polypeptide of at least 100 ng / ml, 5. The pharmaceutical composition according to claim 3, wherein the antigen binding polypeptide is formulated for topical application to the eye and is able to pass through the cornea and into the intraocular space in the absence of a penetration enhancer. The pharmaceutical composition according to claim 3, which is in the form of eye drops. The pharmaceutical composition according to claim 3, which has a pH of less than 8.8. The pharmaceutical composition of claim 1, wherein the polypeptide is sufficiently soluble to pass through one or more epithelial layers in less than about 4 hours. Pharmaceutical1. Фармацевтическая композиция, составленная для локального нанесения на поверхность барьера эпителиальной ткани, содержащая растворимый, антигенсвязывающий полипептид, и фармацевтически приемлемый носитель, разбавитель или эксципиентпричем, в которой указанный полипептид способен проходить, по меньшей мере, че
